Clinical trials: Axillary Hidradenitis Suppurativa
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
- Trial name
- BE HEARD I (NCT04242446)
- Testing
- Bimekizumab
- Where
- 88 sites in United States, Australia and 13 more
- Volunteers
- 505 people
- Sponsor
- UCB Biopharma SRL
Hidradenitis Suppurativa
Allogeneic Micronized Amniotic Membrane Product for the Treatment of Hidradenitis Suppurativa
This study is an open-label, dose-escalation study enrolling 15 participants. There are 3 cohorts: 1. Cohort I: 5 subjects each receiving 1 injection of IGN-AMP001 (12.5mg AMP-001 in 3ml Saline) 2.
- Trial name
- NCT04541550
- Testing
- AMP-001 Low Dose, AMP-001 Medium Dose, AMP-001 High Dose
- Where
- United States
- Sponsor
- IntegoGen, LLC
Hidradenitis Suppurativa, Dermatitis, Atopic
Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic Dermatitis
This non-intervention study will identify the biomarker profiles in hidradenitis suppurativa (HS) and atopic dermatitis (AD) (as a comparator) that would have the most utility in interventional studies evaluating efficacy during…
- Trial name
- NCT04440410
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Kymera Therapeutics, Inc.
Hidradenitis Suppurativa, Acne Inversa
A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa
This study further evaluates the efficacy of bermekimab in treating moderate to severe hidradenitis suppurativa in adults. 1/3 of patients will receive weekly injections of bermekimab, 1/3 will receive alternating every other…
- Conditions
- Hidradenitis Suppurativa, Acne Inversa, Suppurative Hidradenitis
- Trial name
- NCT04019041
- Testing
- bermekimab
- Where
- 33 sites in United States
- Volunteers
- 153 people
- Sponsor
- Janssen Research & Development, LLC
Hidradenitis Suppurativa
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
The purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or interrupted therapy (using a randomized withdrawal period) of two dose regimens…
- Trial name
- NCT04179175
- Testing
- secukinumab
- Where
- 191 sites in United States, Argentina and 36 more
- Volunteers
- 702 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab in adult participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NOVA (NCT03628924)
- Testing
- Guselkumab dose 1, Guselkumab dose 2, Guselkumab dose 3
- Where
- 45 sites in United States, Canada and 4 more
- Volunteers
- 184 people
- Sponsor
- Janssen Research & Development, LLC
Hidradenitis Suppurativa
Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa
This is a randomized, double-blind, placebo-controlled, parallel-group phase 1b study to evaluate AT193 in approximately 44 participants with HS. The treatment period will be 8 weeks followed by a 2-week nontreatment follow-up.
- Trial name
- NCT04989517
- Testing
- AT193
- Where
- 7 sites in Australia
- Volunteers
- 49 people
- Sponsor
- Azora Therapeutics Australia Pty Ltd
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.
- Trial name
- NCT06411899
- Testing
- Sonelokimab
- Where
- 109 sites in United States, Bulgaria and 8 more
- Volunteers
- 422 people
- Sponsor
- MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS) is a skin condition that causes deep, painful bumps on the skin. These bumps usually appear in an area where the skin rubs together.
- Trial name
- NCT07244263
- Testing
- Zasocitinib (Dose A)
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 91 people
- Sponsor
- Takeda
Hidradenitis Suppurativa, Atopic Dermatitis
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort.
- Trial name
- NCT06524635
- Testing
- Lutikizumab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- AbbVie
Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP)
Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists
This study aims to determine if an artificial intelligence (AI) medical device can help healthcare professionals more accurately diagnose rare and complex skin conditions.
- Conditions
- Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP), Eczema Atopic Dermatitis, Acute Generalized Exanthematous Pustulosis
- Trial name
- LegitHealth BI (NCT07428915)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- AI Labs Group S.L
Hidradenitis Suppurativa
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
- Trial name
- BE HEARD EXT (NCT04901195)
- Testing
- Bimekizumab
- Where
- 145 sites in United States, Australia and 17 more
- Volunteers
- 658 people
- Sponsor
- UCB Biopharma SRL
Hidradenitis Suppurativa
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa
This study is open to adults with a chronic inflammatory skin disease called hidradenitis suppurativa. The purpose of this study is to find out whether a medicine called spesolimab helps people with moderate to severe…
- Trial name
- NCT04762277
- Testing
- Spesolimab - solution for infusion, Spesolimab- solution for injection
- Where
- 25 sites in United States, Australia and 10 more
- Volunteers
- 52 people
- Sponsor
- Boehringer Ingelheim
Chronic Urticaria, Idiopathic, Hidradenitis
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
The study duration for an individual subject includes screening (14 days), the treatment period (28 days) and the observational follow-up period of 28 days, in total 70 days ± 6 days.
- Conditions
- Chronic Urticaria, Idiopathic, Hidradenitis, Hidradenitis Suppurativa
- Trial name
- NCT06555328
- Testing
- CSU lower dose treatment, CSU high dose treatment, CSU non responders IgE - high dose treatment
- Where
- 29 sites in United States, Bulgaria and 4 more
- Volunteers
- 73 people
- Sponsor
- InflaRx GmbH
Hidradenitis Suppurativa (HS)
Managed Access Programs for AIN457, Secukinumab
The purpose of this registration is to list Managed Access Programs (MAPs) related to AIN457, secukinumab
- Trial name
- NCT05583604
- Testing
- secukinumab
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis
Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
The primary objective of this study is to demonstrate equivalence of the pharmacokinetic (PK) profile of MSB11022 administered by either an auto-injector (AI) or a pre-filled syringe (PFS) as single subcutaneous (s.c.) injection…
- Conditions
- Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- NCT04018599
- Testing
- 40 mg MSB11022
- Where
- 2 sites in United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Hidradenitis Suppurativa
LTX-109 as Treatment for Hidradenitis Suppurativa
An Open label Phase II//proof of concept-study to demonstrate if percutaneous application of LTX-109 in a gel vehicle is a safe treatment of Hidradenitis suppurativa and to identify clinical response to intervention, as well to…
- Trial name
- NCT04756336
- Testing
- LTX-109 gel, 3% w/w
- Where
- Norway
- Volunteers
- 11 people
- Sponsor
- Pharma Holdings AS
Hidradenitis Suppurativa
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin…
- Trial name
- Intrepid (NCT06468228)
- Testing
- Lutikizumab
- Where
- 279 sites in United States, Argentina and 42 more
- Volunteers
- 1,400 people
- Sponsor
- AbbVie
Skin Lesions, Melanocytic Nevi
Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions.
This study aims to determine if an artificial intelligence (AI) medical device can help primary care doctors more accurately identify and manage various skin conditions.
- Conditions
- Skin Lesions, Melanocytic Nevi, Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin
- Trial name
- LegitHealth PH (NCT07428941)
- Testing
- AI-based medical device for aided diagnosis in dermatological conditions
- Where
- Spain
- Volunteers
- 9 people
- Sponsor
- AI Labs Group S.L
Hidradenitis Suppurativa
A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS
This study aims to better understand how Bruton's tyrosine kinase (BTK) inhibition with remibrutinib works in hidradenitis suppurativa (HS), a complex inflammatory disease with different types of lesions.
- Trial name
- NCT07855276
- Testing
- LOU064
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals